Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
PHOENIX — Prosecutors have agreed to create a statewide database of officers whose truthfulness or honesty may be questionable. But an attorney with the American Civil Liberties Union says it appears ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback